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Background: Leptomeningeal metastasis of melanoma is a devastating complication with a grave prognosis, and
there are no known effective standard treatments. Although selective BRAF inhibitors have demonstrated a significant
clinical activity in patients with metastatic melanoma harboring a BRAF mutation, the clinical benefit of BRAF
inhibitor-based therapy in leptomeningeal disease is not clear.
Case presentation: We present a case of prolonged survival of a patient with BRAF V600E-mutant leptomeningeal
disease who was treated with vemurafenib followed by whole brain radiation and a combination of dabrafenib
and trametinib. Both vemurafenib and the sequential treatment of radiation and dabrafenib/trametinib led to
regression of the leptomeningeal disease, and the patient survived for 19 months after the diagnosis of the
leptomeningeal disease.
Conclusion: This case suggests a possible clinically meaningful benefit of BRAF inhibitor-based therapy and a
need for close investigation of this therapeutic approach in patients with this devastating disease.
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Leptomeningeal disease (LMD) defined as the infiltra-
tion of cancer cells in pia mater and arachnoid mem-
brane is a devastating and lethal complication of cancer.
It is diagnosed by a combination of suggestive symptoms
and signs (often indicating dysfunction of the nervous
system at multiple levels), the presence of cancer cells
within the cerebrospinal fluid (CSF) and/or demonstra-
tion of leptomeningeal enhancement on a magnetic res-
onance imaging (MRI) scan [1]. Malignant melanoma is
one of the most common solid tumors with predilection
to leptomeningeal metastasis, occurring in up to 23 % of
patients with melanoma [2], and patients with metastatic
melanoma involving the leptomeninges have the worst
prognosis among all patients with solid tumor-related
LMD [3]. The median overall survival of melanoma* Correspondence: kimkb@sutterhealth.org
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unless otherwise stated.patients with LMD is only 8–10 weeks [3, 4]. The inci-
dence of LMD has increased over the years [5] and may
continue to increase, likely due to the improved overall
survival and a prolonged control of extracranial disease
with newly approved systemic therapeutic drugs, such as
anti-cytotoxic T-lymphocyte antigen (CTLA)-4 antibody
and BRAF inhibitors. Unfortunately, there are no known
effective therapeutic options for LMD in patients with
metastatic melanoma. Therefore, new effective thera-
peutic modalities are needed for the treatment of LMD.
The rapid technical advances in the molecular and
genetic analysis of melanoma have led to the identifica-
tion of mutations in the BRAF gene in melanoma and
the development of targeted therapy for BRAF-mutant
metastatic melanoma. Approximately 50 % of all mela-
nomas contain a kinase-activating BRAF mutation at
codon 600 of exon 15, a majority of which with a substi-
tution of valine with glutamic acid (V600E) [6]. Without
treatment with selective BRAF inhibitors, patients with
BRAF V600E-mutant melanoma generally have a pooreris is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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selective BRAF inhibitors, such as vemurafenib and dab-
rafenib, have a significant clinical activity with a clinical
response rate of ~50 % and a median progression-free
survival duration of nearly 7 months, prompting the ap-
proval of these drugs by the Food and Drug Administra-
tion (FDA) in the United States [8-11]. Interestingly, a
phase II study of dabrafenib demonstrated that it also
has a clinically meaningful clinical activity in the brain
in patients with metastatic melanoma harboring a BRAF
V600E mutation, similar to its activity in the extracranial
organs [12]. However, the clinical activity of the BRAF
inhibitors or BRAF inhibitor-based combination regi-
mens in LMD has not been established yet. Here, we re-
port a patient with BRAF-mutant metastatic melanoma
who had a great clinical response in the LMD and an
unexpectedly long survival with BRAF inhibitor-based
treatment.
Case presentation
A 61-year-old male, was diagnosed with 5.5 mm thick,
Clark level IV, nodular melanoma without ulcerations on
his right back in May of 2007. He underwent a wide
local excision of the primary melanoma and a sentinelFig. 1 Brain MRI showing the response and the progression of the leptome
the enhancement of the leptomeninges in April 2013. After vemurafenib thera
disease. He had progression of the leptomeningeal disease in October 2013 an
The follow-up scans showed regressed leptomeningeal diseasenode biopsy in the right axilla, which revealed one
lymph node positive for metastatic melanoma. He subse-
quently underwent a lymph node dissection of the right
axilla; none of 32 lymph nodes was positive for meta-
static melanoma. After the lymph node dissection, a
computed tomography (CT) scan of the body revealed
no evidence of metastatic disease. He was fine until
September of 2009, when he had a solitary metastatic
melanoma in the left lung, for which he underwent left
upper lobe lingular-sparing lobectomy with the resection
of the nodule in November of 2009. He remained free of
disease until November of 2011, when he was found to
have new metastatic lesions in the right middle lobe of
lung and peritoneum, and he received 4 doses of ipili-
mumab (3 mg/kg) and then, 2 doses of the combination
of TPI-287 (abeotaxane) and temozolomide with further
progression of the peritoneal lesions and stable disease
in the lung. Subsequently, in June of 2012, the peritoneal
lesions were surgically resected. However, in April of
2013, a MRI scan of the brain revealed multiple paren-
chymal metastatic lesions and clear leptomeningeal en-
hancement spread to the left cerebellar sulci and the left
frontal cortical sulci (Fig. 1). His spinal MRI was normal.
He had no neurological symptoms related to the LMD.ningeal disease with BRAF inhibitor-based therapy. The arrows indicate
py, the follow-up images revealed initial regression of the leptomeningeal
d started whole brain radiation followed by dabrafenib plus trametinib.
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oma cells. A CT scan of the body also revealed progres-
sion of the lung lesions and new peritoneal masses. He
started treatment with vemurafenib at 960 mg twice a
day since a molecular analysis showed that his primary
melanoma harbored a BRAF V600E mutation. He toler-
ated the treatment well with mild photosensitivity. In
June of 2013, a MRI scan of the brain revealed improve-
ment with decrease in size of parenchymal metastatic le-
sions and regression of leptomeningeal disease (Fig. 1).
A CSF examination showed no malignant cells. In
addition, a CT scan of the body also demonstrated clin-
ical response in the lung and peritoneal metastatic le-
sions. Follow-up scans revealed further improvement of
LMD in August of 2013. Unfortunately, he had disease
progression in the brain, leptomeninges, peritoneum and
subcutaneous lesions in October of 2013 (Fig. 1). He was
treated with whole brain radiation followed by the com-
bination of dabrafenib and trametinib in November of
2013. He developed moderate fatigue from the treat-
ment, which resolved with decreased dose of dabrafenib
and trametinib. A MRI scan of the brain demonstrated
improvement of the LMD and brain parenchymal meta-
static disease in December of 2013 and February of
2014. As of the most recent follow-up evaluation in
April of 2014, a MRI scan of the brain showed continued
disease response in all metastatic sites including the
leptomeninges and brain parenchyma (Fig. 1). The pa-
tient remained free of neurological symptoms through-
out the treatment duration. However, his extracranial
metastatic disease progressed in the peritoneum and the
subcutaneous tissues and he expired in October of 2014
which is 19 months after the diagnosis of brain and
leptomeningeal metastases.
Conclusions
In our report, we presented a case of an unexpectedly
prolonged survival in a patient with metastatic melan-
oma involving the brain and leptomeninges with BRAF
inhibitor-based therapy. The clinical response to each of
the BRAF inhibitor-based treatments was demonstrated
both radiographically and cytologically. The patient tol-
erated the treatment without development of signs or
symptoms suggestive of worsening LMD. Considering
that the median overall survival duration of patients with
LMD from melanoma is only 8–10 weeks [3, 4], our pa-
tient truly had a clinically meaningful benefit from this
therapeutic approach.
LMD remains a devastating complication of cancer
despite the significant improvement in overall survival of
patients with metastatic melanoma with new effective
systemic treatments, including selective BRAF inhibitors
and anti-CTLA-4 antibody. The impact of these drugs in
the clinical outcome of patients with LMD is not known.Typically, for patients with LMD, comfort care or pallia-
tive radiation therapy to areas of bulky or symptomatic
disease is considered because of the lack of known effect-
ive treatment. Although several case studies published
over the decades have demonstrated a response or
stabilization of LMD with radiation, systemic treatment
with temozolomide or ipilimumab, intrathecal interleukin-
2 or intrathecal liposomal cytarabine [3, 13–16], these rare
successes remain anecdotal, and it is generally accepted
that these treatments do not prolong survival.
Recently, two cases of LMD from BRAF V600E-mutant
melanoma have shown clinical responses to vemurafenib-
containing treatment [17, 18]. However, since the two
patients were treated not only with vemurafenib but also
with other therapies including intrathecal liposomal cytar-
abine and sequential whole-brain radiation either immedi-
ately or 1–3 months prior to vemurafenib, it is not clear
whether the responses in the LMD resulted from a pure
vemurafenib effect or from the combination with other
treatment modalities, such as a late response from the
radiation therapy. In contrast to these published cases, our
patient initially received only vemurafenib for the treat-
ment of LMD. Although our patient was previously
treated with ipilimumab and systemic chemotherapy, the
treatment was completed more than 1 year before the
patient developed LMD. Therefore, it is unlikely that
the response in the leptomeninge is secondary to the late
effect of the previous treatments.
Unfortunately, our patient had progression of the
LMD and the extracranial lesions after 6 months of the
response with single agent vemurafenib treatment, which
approximates the median progression free survival dur-
ation with vemurafenib treatment [8, 9]. Interestingly, the
relapse of the LMD responded to whole brain radiation
followed by the dabrafenib plus trametinib treatment.
Trametinib is a selective inhibitor of MEK1/MEK2
which is the only known substrate of BRAF kinase in the
mitogen-activated protein kinase (MAPK) pathway. As
the reactivation of the MAPK signaling pathway is one
of the most important mechanisms of resistance to
BRAF inhibitor therapy, a combination of BRAF inhibi-
tor and MEK inhibitor to more completely block the
pathway is a rational approach to delay the resistance.
Recently, two phase III studies demonstrated the super-
iority of a combination of dabrafenib and trametinib
over a single agent BRAF inhibitor in treatment-naïve
patients with advanced melanoma harboring a V600
BRAF mutation [19, 20]. However, its clinical benefit in
patients whose metastatic melanoma progressed on a
prior BRAF inhibitor treatment is only modest at best
[21]. In addition, the response in this setting is mostly
observed in the extracranial organs, and there are no
published data regarding the clinical efficacy of dabra-
fenib plus trametinib in LMD resistant to a BRAF
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extracranial lesions were not as responsive to the com-
bination of dabrafenib and trametinib as the lesions in
the brain and the leptomeninges. Therefore, we can
speculate that the radiation therapy to the brain might
have enhanced the efficacy of the targeted drugs by
either synergizing antitumor activity with the drugs or
simply allowing better drug penetration to and accumu-
lation in the CSF [22]. Controlled preclinical and clinical
studies will need to be conducted to delineate the mech-
anisms of action and the therapeutic role of radiation in
this combination approach.
The brain, CSF and meningeal membrane are known
as sanctuary sites from toxins and drugs due to the pres-
ence of the blood-brain barrier [23]. Although several
strategies including intrathecal treatment and a combin-
ation of systemic therapy and radiation have been used
to overcome this barrier and enhance drug delivery in
CSF, the clinical outcome of patients with LMD is still
poor. One possible explanation for the leptomeningeal
response in our patient with vemurafenib is the con-
current presence of multiple parenchymal metastases
which might have disrupted the blood-brain barrier and
allowed a higher level of vemurafenib in the CSF. Since
vemurafenib is much more effective in the BRAF-mu-
tated metastatic melanoma lesions than cytotoxic drugs,
the clinical effect might have been more noticeable in
the leptomeninges. This speculation is consistent with
the finding that the blood-brain barrier permeability is
increased up to 22 % in and around brain tumor com-
pared with normal brain tissue [24, 25].
The possible drug accumulation in the CSF can also
be suggested by the fact that the expression level of a
P-glycoprotein, a multidrug resistance protein, which
effluxes drugs out of the central nervous system (CNS),
is 70–95 % lower in metastatic melanoma than normal
brain tissue [25, 26]. In addition, the angiogenesis associ-
ated with the progression of melanoma into the lepto-
meninges results in an abnormal and leaky blood-brain
barrier [25, 27], which may further increase vemurafenib
or dabrafenib concentration in CSF, though no data re-
garding the vemurafenib concentrations in the CSF of
patients with brain metastases are available. Unfortu-
nately, we could not measure the drug concentration in
the CSF for our patient.
In our patient, the LMD was detected by a routine im-
aging test, and he did not have any symptoms to suggest
LMD. The early detection of the LMD in our patient may
explain the survival of longer than 1.5 years, since LMD
without neurological deficits is associated with good re-
sponse to treatment [27, 28]. Our speculation is supported
by the finding that patients with low tumor burden of
metastatic melanoma have a statistically longer median
progression-free survival duration with vemurafenib thanthose with high tumor burden [29, 30]. However, the pro-
longed survival of our patient is much more remarkable
than we expected, since median overall survival duration
is only 2.9 months in patients with LMD without neuro-
logic signs or symptoms [31].
The prolonged survival in our patient with BRAF
inhibitor-based therapy is very encouraging for the man-
agement of patients with melanoma and LMD. Certainly,
this approach is not applicable for those with wild-type
BRAF melanoma, but for those with the BRAF-mutant
LMD, we hope that our case will spark the interest in
well-designed studies to evaluate BRAF inhibitor-based
therapy with or without radiation therapy. If this com-
bination therapy is proven effective, it could potentially
replace palliative radiation therapy as the preferred
therapeutic modality, especially in BRAF inhibitor-naive
patients with BRAF-mutant melanoma who also have
extracranial metastases.
In addition, clinical studies of checkpoint inhibitors,
such as anti-CTLA4 antibodies and anti-program death
(PD)-1 antibodies, will be needed to improve the disease
control in patients with LMD in the future.
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